TABLE 6.
Type of advanced therapy | Cells | Type of hMSC treatment evaluated | Animals | Disease models | Follow-up | References |
Cell therapy and gene therapy | hUCB-MSCs | 1-hUCB-MSC group: 2 × 106 cells injected subcutaneously 24 h before and at day 6 of imiquimod application 2-hUCB-MSC-transduced group: 2 × 106 cells transduced with extracellular superoxide dismutase (SOD3) and injected subcutaneously 24 h before and at day 6 of imiquimod application 3-Control group: subcutaneous injections of an equal volume of phosphate-buffered saline at the same time points | – C57BL/6 mice | A mouse model of IMQ-induced psoriasis-like inflammation | 12 days | Sah et al., 2016 |
Cell therapy | hUCB-MSCs | 1-hUCB-MSC group: 2 × 106 cells were injected subcutaneously on day 1 and 7 after induction of psoriasis-like skin 2-Control group: subcutaneous injections of an equal volume of phosphate-buffered saline at the same time points | – C57/BL6 male mice | IL-23-mediated psoriasis-like skin inflammation mouse model IMQ-induced psoriasis-like skin inflammation mouse model | 15 days | Lee et al., 2017 |
hPT-MSCs | 1-hPT-MSC group: 106 cells via the mouse tail vein on days 1 and 3 of the imiquimod application period 2-Control group: Mice received an intravenous injection of an equal volume of phosphate-buffered saline (PBS) via tail vein at the same time points | – Female C57BL/6 mice | IMQ-induced psoriasis-like skin inflammation mouse model | 7 days | Kim J.Y. et al., 2018 | |
hA-MSCs | 1-hA-MSC group: 2 × 105 cells injected intravenously 2-Control group: mouse serum injected intravenously | – B6 mice | A mouse model of IMQ-induced psoriasis-like inflammation | 5 days | Imai et al., 2019 | |
hUCB-MSCs | 1-hUCB-MSC group: 1 × 105 cells injected intravenously 2-Control group: phosphate-buffered saline injected intravenously | – Female BALB/c mice | A mouse model of IMQ-induced psoriasis-like inflammation | 13 days | Chen et al., 2019 |